COVID-19 vaccine - Panacea Biotec - Refana (JV)
Alternative Names: Inactivated viral vaccine - Panacea Biotec/RefanaLatest Information Update: 28 Jul 2024
At a glance
- Originator Panacea Biotec - Refana (JV)
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in Ireland (Parenteral)
- 10 Jun 2020 Panacea Biotec enters into a research, development and marketing agreement with Refana for COVID-19 vaccine
- 10 Jun 2020 Early research in COVID-2019 infections in Ireland (Parenteral)